文献速递免疫规划卫生政策与健康促进

疫苗合作的艺术:DCVMN第19届年会综述

The art of partnerships for vaccines.
PubMed 文献 · Vaccine · 2019-08-22

发展中国家疫苗制造商网络(DCVMN)第19届年会汇集疫苗制造专家与公共卫生组织领导人,围绕国际合作促进疫苗可及性、从研发到应急响应的伙伴关系、全球疫苗市场趋势与融资采购变化展开讨论。成员单位报告了六价疫苗、脑膜炎、肺炎球菌结合疫苗、志贺菌、腮腺炎、轮状病毒、黄热病、脊髓灰质炎、戊型肝炎和登革热疫苗及狂犬病暴露后单克隆抗体鸡尾酒的研发进展。会议强调共享质量控制最佳实践、减少重复检测、促进统一标准、加入WHO生物制品国家控制实验室网络、推动监管趋同与联合审评可加速全球疫苗可及性。

要点

  • 广泛利益相关方合作可支持并加速疫苗创新、临床试验、注册、WHO预认证、引入和可及性
  • 共享质量控制最佳实践、减少重复检测和促进统一标准可增强疫苗可及性与可用性
  • 区域和全球监管趋同、联合审评和WHO协作注册程序有助于加速全球疫苗可及性

核心结论

  • 基于经验与信任的强有力伙伴关系有助于利用机会,对推进为所有人提供优质疫苗的共同目标至关重要。

研究设计与样本

  • DCVMN第19届年会汇集疫苗制造专家及地方和全球公共卫生组织领导人,通过讲座和专题讨论进行交流。

主要发现

  • 成员单位报告了六价疫苗、脑膜炎疫苗、肺炎球菌结合疫苗、志贺菌疫苗、腮腺炎疫苗、轮状病毒疫苗、黄热病疫苗、脊髓灰质炎疫苗、戊型肝炎疫苗和登革热疫苗的研发进展。
  • 成员单位还报告了用于狂犬病感染暴露后预防的新型单克隆抗体鸡尾酒的研发进展。
  • 会议讨论了全球疫苗市场趋势及将影响疫苗融资和采购方法的变化,以及包括资金在内的新疫苗或改良疫苗开发的资本来源。
  • 会议讨论了通过联合档案审评和WHO协作注册程序等机制加强区域和全球监管趋同,以及四项简化程序和统一档案的提案。

临床怎么用

  • 鼓励符合条件的利益相关方加入WHO生物制品国家控制实验室网络,作为该领域合作和技术交流的平台。
  • 通过共享疫苗质量控制最佳实践、减少重复检测和促进统一共同标准,增强疫苗可及性和可用性。
  • 利用区域和全球监管趋同机制(如联合档案审评和WHO协作注册程序)加速全球疫苗可及性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Developing Countries Vaccine Manufacturers Network (DCVMN) convened vaccine manufacturing experts and leaders from local and global public health organizations for its 19th Annual General Meeting. Lectures and panel discussions centered on international cooperation for better access to vaccines, and partnerships in areas ranging from vaccine research and process development, to clinical studies, regulatory, supply chain and emergency preparedness and response. Global vaccine market trends and changes that will impact vaccine financing and procurement methods were discussed as well as capital sources, including funding, for the development of new or improved vaccines. DCVMN members presented their progress in developing novel Hexavalent, Meningitis, Pneumococcal Conjugate Vaccine, Shigella, Mumps, Rotavirus, Yellow Fever, Polio, Hepatitis E and Dengue vaccines, and a novel monoclonal antibody cocktail for post-bite prophylaxis against rabies infections. Access to and availability of vaccines is enhanced through sharing of best practices for vaccine quality control, reducing redundant testing and promoting development of harmonized common standards. Eligible stakeholders were encouraged to join the WHO-National Control Laboratory Network for Biologicals which serves as a platform for collaboration and technical exchange in this area. Increasing regulatory convergence at the regional and global levels through mechanisms such as joint dossier review and the WHO Collaborative Registration Procedure can help to accelerate vaccine access globally. Additionally, four proposals for streamlining procedures and alignment of dossiers were discussed. Successful partnerships between a broad range of stakeholders, including international organizations, manufacturers, academic research institutes and regulators have provided support for, and in some cases accelerated, vaccine innovation, clinical trials and registration, WHO prequalification, vaccine introduction and access. Strong partnerships, based on experience and trust, help leverage opportunities and are critically important to advancing the shared goal of providing quality vaccines for all people.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pagliusi S, Che Y, Dong S, et al. The art of partnerships for vaccines. Vaccine. 2019. PMID: 31447125. doi:10.1016/j.vaccine.2019.07.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。